Global (United States, European Union and China) Ophthalmic Therapeutics/Drug Market Research Report 2019-2025

2 Global Ophthalmic Therapeutics/Drug Quarterly Market Size Analysis

• 2.1 Ophthalmic Therapeutics/Drug Business Impact Assessment - COVID-19
  • 2.1.1 Global Ophthalmic Therapeutics/Drug Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
• 2.2 Global Ophthalmic Therapeutics/Drug Quarterly Market Size 2020-2021
• 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
  • 2.3.1 Drivers
  • 2.3.2 Restraints
  • 2.3.3 Opportunities
  • 2.3.4 Challenges

3 Quarterly Competitive Assessment, 2020

• 3.1 By Players, Global Ophthalmic Therapeutics/Drug Quarterly Market Size, 2019 VS 2020
• 3.2 By Players, Ophthalmic Therapeutics/Drug Headquarters and Area Served
• 3.3 Date of Key Players Enter into Ophthalmic Therapeutics/Drug Market
• 3.4 Key Players Ophthalmic Therapeutics/Drug Product Offered
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Impact of Covid-19 on Ophthalmic Therapeutics/Drug Segments, By Type

• 4.1 Introduction
  • 1.4.1 Anti-allergy
  • 1.4.2 Anti-VEGF Agents
  • 1.4.3 Anti-inflammatory
  • 1.4.4 Anti-glaucoma
  • 1.4.5 Others
• 4.2 By Type, Global Ophthalmic Therapeutics/Drug Market Size, 2019-2021

5 Impact of Covid-19 on Ophthalmic Therapeutics/Drug Segments, By Application

• 5.1 Overview
  • 5.5.1 Dry Eye
  • 5.5.2 Allergies
  • 5.5.3 Glaucoma
  • 5.5.4 Infection
  • 5.5.5 Retinal Disorders
  • 5.5.6 Uveitis
  • 5.5.7 Others
• 5.2 By Application, Global Ophthalmic Therapeutics/Drug Market Size, 2019-2021
  • 5.2.1 By Application, Global Ophthalmic Therapeutics/Drug Market Size by Application, 2019-2021

6 Geographic Analysis

• 6.1 Introduction
• 6.2 North America
  • 6.2.1 Macroeconomic Indicators of US
  • 6.2.2 US
  • 6.2.3 Canada
• 6.3 Europe
  • 6.3.1 Macroeconomic Indicators of Europe
  • 6.3.2 Germany
  • 6.3.3 France
  • 6.3.4 UK
  • 6.3.5 Italy
• 6.4 Asia-Pacific
  • 6.4.1 Macroeconomic Indicators of Asia-Pacific
  • 6.4.2 China
  • 6.4.3 Japan
  • 6.4.4 South Korea
  • 6.4.5 India
  • 6.4.6 ASEAN
• 6.5 Rest of World
  • 6.5.1 Latin America
  • 6.5.2 Middle East and Africa

7 Company Profiles

• 7.1 Alcon
  • 7.1.1 Alcon Business Overview
  • 7.1.2 Alcon Ophthalmic Therapeutics/Drug Quarterly Revenue, 2020
  • 7.1.3 Alcon Ophthalmic Therapeutics/Drug Product Introduction
  • 7.1.4 Alcon Response to COVID-19 and Related Developments
• 7.2 Johnson and Johnson Vision Care, Inc.
  • 7.2.1 Johnson and Johnson Vision Care, Inc. Business Overview
  • 7.2.2 Johnson and Johnson Vision Care, Inc. Ophthalmic Therapeutics/Drug Quarterly Revenue, 2020
  • 7.2.3 Johnson and Johnson Vision Care, Inc. Ophthalmic Therapeutics/Drug Product Introduction
  • 7.2.4 Johnson and Johnson Vision Care, Inc. Response to COVID-19 and Related Developments
• 7.3 Bausch & Lomb Incorporated
  • 7.3.1 Bausch & Lomb Incorporated Business Overview
  • 7.3.2 Bausch & Lomb Incorporated Ophthalmic Therapeutics/Drug Quarterly Revenue, 2020
  • 7.3.3 Bausch & Lomb Incorporated Ophthalmic Therapeutics/Drug Product Introduction
  • 7.3.4 Bausch & Lomb Incorporated Response to COVID-19 and Related Developments
• 7.4 Novartis AG
  • 7.4.1 Novartis AG Business Overview
  • 7.4.2 Novartis AG Ophthalmic Therapeutics/Drug Quarterly Revenue, 2020
  • 7.4.3 Novartis AG Ophthalmic Therapeutics/Drug Product Introduction
  • 7.4.4 Novartis AG Response to COVID-19 and Related Developments
• 7.5 Merck Sharp & Dohme Corp.
  • 7.5.1 Merck Sharp & Dohme Corp. Business Overview
  • 7.5.2 Merck Sharp & Dohme Corp. Ophthalmic Therapeutics/Drug Quarterly Revenue, 2020
  • 7.5.3 Merck Sharp & Dohme Corp. Ophthalmic Therapeutics/Drug Product Introduction
  • 7.5.4 Merck Sharp & Dohme Corp. Response to COVID-19 and Related Developments
• 7.6 Regeneron Pharmaceuticals Inc.
  • 7.6.1 Regeneron Pharmaceuticals Inc. Business Overview
  • 7.6.2 Regeneron Pharmaceuticals Inc. Ophthalmic Therapeutics/Drug Quarterly Revenue, 2020
  • 7.6.3 Regeneron Pharmaceuticals Inc. Ophthalmic Therapeutics/Drug Product Introduction
  • 7.6.4 Regeneron Pharmaceuticals Inc. Response to COVID-19 and Related Developments
• 7.7 Allergan
  • 7.7.1 Allergan Business Overview
  • 7.7.2 Allergan Ophthalmic Therapeutics/Drug Quarterly Revenue, 2020
  • 7.7.3 Allergan Ophthalmic Therapeutics/Drug Product Introduction
  • 7.7.4 Allergan Response to COVID-19 and Related Developments
• 7.8 Pfizer Inc.
  • 7.8.1 Pfizer Inc. Business Overview
  • 7.8.2 Pfizer Inc. Ophthalmic Therapeutics/Drug Quarterly Revenue, 2020
  • 7.8.3 Pfizer Inc. Ophthalmic Therapeutics/Drug Product Introduction
  • 7.8.4 Pfizer Inc. Response to COVID-19 and Related Developments
• 7.9 Valeant
  • 7.9.1 Valeant Business Overview
  • 7.9.2 Valeant Ophthalmic Therapeutics/Drug Quarterly Revenue, 2020
  • 7.9.3 Valeant Ophthalmic Therapeutics/Drug Product Introduction
  • 7.9.4 Valeant Response to COVID-19 and Related Developments
• 7.10 Bayer AG
  • 7.10.1 Bayer AG Business Overview
  • 7.10.2 Bayer AG Ophthalmic Therapeutics/Drug Quarterly Revenue, 2020
  • 7.10.3 Bayer AG Ophthalmic Therapeutics/Drug Product Introduction
  • 7.10.4 Bayer AG Response to COVID-19 and Related Developments
• 7.11 Santen Pharmaceuticals Co. Ltd
  • 7.11.1 Santen Pharmaceuticals Co. Ltd Business Overview
  • 7.11.2 Santen Pharmaceuticals Co. Ltd Ophthalmic Therapeutics/Drug Quarterly Revenue, 2020
  • 7.11.3 Santen Pharmaceuticals Co. Ltd Ophthalmic Therapeutics/Drug Product Introduction
  • 7.11.4 Santen Pharmaceuticals Co. Ltd Response to COVID-19 and Related Developments
• 7.12 Genentech, Inc.
  • 7.12.1 Genentech, Inc. Business Overview
  • 7.12.2 Genentech, Inc. Ophthalmic Therapeutics/Drug Quarterly Revenue, 2020
  • 7.12.3 Genentech, Inc. Ophthalmic Therapeutics/Drug Product Introduction
  • 7.12.4 Genentech, Inc. Response to COVID-19 and Related Developments

8 Key Findings

9 Appendix

• 9.1 About US